Results 131 to 140 of about 2,331,072 (216)

Neuropathic Pain: From Mechanisms to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Neuropathic pain arises from peripheral nerve injury, central sensitization, neurotransmitter imbalance, neuroimmune activation, and maladaptive circuit remodeling. Clinical phenotyping and multimodal imaging can identify dominant peripheral and central mechanisms.
Yaling Dai   +8 more
wiley   +1 more source

The impact of Transcranial Magnetic Stimulation (TMS) on seizure course in people with and without epilepsy. [PDF]

open access: yesClin Neurophysiol Pract, 2022
Pang S   +8 more
europepmc   +1 more source

Movement Disorders in Developmental and Epileptic Encephalopathies

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 10, Page 2328-2340, October 2026.
Abstract Background Monogenic developmental and epileptic encephalopathies (DEE) frequently feature co‐occurring movement disorders. Gene discovery has expanded epilepsy‐dyskinesia syndromes (EDS) from classic associations such as stereotypies in Rett syndrome to PRRT2‐related infantile seizures with paroxysmal dyskinesia and crouched gait in SCN1A ...
Shekeeb Mohammad   +2 more
wiley   +1 more source

A magnetic stimulation examination of orthographic neighborhood effects in visual word recognition [PDF]

open access: yes, 2003
The split-fovea theory proposes that visual word recognition is mediated by the splitting of the foveal image, with letters to the left of fixation projected to the right hemisphere (RH) and letters to the right of fixation projected to the left ...
Walsh, V., Lavidor, M.
core  

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 10, Page 2500-2508, October 2026.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau   +3 more
wiley   +1 more source

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 10, Page 2539-2545, October 2026.
Abstract Background Reduced cardiac uptake on 123Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions.
Frank Jagusch   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy